05-17655. Medicare Program; Competitive Acquisition of Outpatient Drugs and Biologicals Under Part B: Interpretation and Correction
-
Start Preamble
AGENCY:
Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION:
Interim final rule; interpretation and correction.
SUMMARY:
This interim final rule clarifies our timeline for implementation of the competitive acquisition program under section 1847B of the Social Security Act and corrects technical errors that appeared in the addenda to the interim final rule with comment period published in the Federal Register on July 6, 2005 entitled “Competitive Acquisition of Outpatient Drugs and Biologicals Under Part B.”
EFFECTIVE DATE:
This rule is effective September 6, 2005.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Lia Prela, (410) 786-0548.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
I. Background
A. Clarification of Timeline for Implementation of CAP
On July 6, 2005, we published an interim final rule with comment period (70 FR 39022) in the Federal Register with respect to provisions of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) that require the implementation of a competitive acquisition program (CAP) for certain Medicare Part B drugs not paid on a cost or prospective payment system basis. Physicians will generally be given a choice between obtaining these drugs from vendors selected through a competitive bidding process or directly purchasing these drugs and being paid under the average sales price (ASP) system.
In the July 6, 2005 interim final rule, we stated that implementation of the CAP would take place on January 1, 2006 to coordinate the CAP physician election process with the Medicare participating physician election process described in section 1842(h) of Social Security Act (the Act). Subsequent to the publication of the July 6, 2005 interim final rule, we received comments requesting a delay in implementation of the CAP from a variety of sources including written public comments as well as comments voiced during the conference call for potential vendors that we held on July 8, 2005.
Effective August 3, 2005, we suspended the vendor bidding process that began with publication of the interim final rule on July 6, 2005, to allow us more time to fully review public comments on the interim final rule and also to further refine the bidding process. We provided notification of the suspension on the CMS Web site http://www.cms.hhs.gov/providers/drugs/compbid/ and through the pharmacy and physician Listservs. We will publish a final rule for implementing the CAP after we analyze the additional comments on the interim final rule and determine the best manner for improving the efficiency of the CAP and increasing potential participation of both vendors and physicians in the program.
We will announce the dates for the new vendor bidding period concurrent with the publication of the final rule. We also will be announcing a special physician election period. Currently, we expect that drugs will first be delivered through the CAP by July 2006. During the special election period, physicians will have the opportunity to elect to participate in the CAP from its start date in 2006 through the end of calendar year 2006.
As we specified in the July 2005 Federal Register document, we will continue to accept comments on the interim final rule until September 6, 2005.
In section II of this document, we provide clarification of the timeline for implementation of the CAP as well as further interpretation of what will Start Printed Page 52931constitute an “exigent circumstance” for purposes of allowing a physician to elect to participate in the CAP and select a CAP vendor at a time other than the annual election period.
B. Corrections to the July 6, 2005 Interim Final Rule
In FR Doc. 05-12938 of July 6, 2005 (70 FR 39022), we identified errors to Addendum A and Addendum B that are corrected under “Correction of Addenda Errors” in section III of this document. These corrections are effective as if they had been included in the document published July 6, 2005.
II. Delay in Implementation Date
On March 4, 2005, we published a proposed rule (70 FR 10746) to implement a CAP program, as required by section 1847B of the Act, as added by section 303(d) of the MMA, for certain Medicare Part B drugs not paid on a cost or prospective payment system basis. In response to the proposed rule, commenters expressed concern about the short timeframe for implementation of the CAP, that is, the proposed January 1, 2006 effective date stated in the July 6, 2005 interim final rule. These commenters suggested we delay the effective date of the CAP to allow us to fully structure the CAP to meet congressional objectives and benefit physicians without compromising beneficiary access to drug therapies and treatment.
We responded to those comments in the July 6, 2005 interim final rule (70 FR 39025) by stating that we recognized that the timeframe for implementation was ambitious but we believed that the regulatory framework provided a firm basis for implementing the CAP in January 2006.
We also stated that the statute requires that we coordinate the physicians' election to participate in the CAP with the Medicare Participating Physician Process described in section 1842(h) of the Act.
However, upon further consideration of these comments, as well as additional feedback we have received from potential participants in the program, we have concluded that more time is needed to further refine the program before implementation. After reviewing public comments, we agree that a short delay in implementing the CAP will allow us to improve the efficiency of the program and increase interest in participating in the program. Therefore, in accordance with our authority to phase-in the program as appropriate during 2006, we are delaying implementation of the CAP. The CAP program will not begin on January 1, 2006, and the initial physician election process will not occur in 2005.
As noted above, we intend to implement the CAP during 2006 and we expect that the CAP program will begin sometime in or around July 2006. In addition, we expect the initial physician election period to occur in the spring of 2006 rather than in fall 2005. We consider the initial implementation of the CAP program to constitute an “exigent circumstance” for purposes of section 1847B(a)(5)(A)(i) of the Act and § 414.908(a)(2) of our regulations, which allow for a physician election period at times other than the regular, annual election period. We are specifying the initial election period as an “exigent circumstance” because we intend the program to run on a calendar year basis, as stated in the July 2005 interim final rule, after the initial implementation of the CAP in 2006. In later years, the annual CAP election period will be coordinated with the annual Medicare Participating Physician Enrollment Process described in section 1842(h) of the Act, which occurs in the fall of each year, as specified in the July 2005 interim final rule.
We believe that, after the initial election period in 2006, an annual election period that ends on November 15 before the beginning of each CAP year is still necessary to allow time for the carrier, the designated carrier, the vendors, and our claims processing system to complete tasks in preparation for that CAP year. We expect to include the dates of the initial physician election period in the final rule. Physicians will then be provided with a second election period in 2006 for participation in the CAP in 2007.
In the July 6, 2005 interim final rule, we stated in several other places in the preamble that the CAP would begin on January 1, 2006.
For example, we referred to a January 1, 2006 start date in our discussion of the activities that would be necessary to implement the CAP on that date. These included CAP operations, analysis and coding of the CAP claims processing system, and educating beneficiaries and physicians about the program. In the July 2005 interim final rule, we specified that in response to the March 2005 proposed rule, several commenters expressed concern about introducing the CAP so quickly without any formal testing or analysis of the program. Other commenters expressed concern about education and outreach efforts relating to the CAP. Our decision to suspend the current vendor bidding process and delay the start date of the CAP will allow time for refining CAP operations, additional testing of the claims processing system, and for further beneficiary, physician, and vendor applicant educational efforts. We believe this additional preparation time will greatly improve and ease the implementation process.
III. Correction of Addenda Errors
In the July 6, 2005 interim final rule, Addendum A “Single Drug Category List” does not include the column reflecting the weights assigned to each CAP drug that will be used in computing the composite bids. In this interim final rule, we are correcting the error by republishing Addendum A in its entirety, with the third column included. In addition, in Addendum B, “New Drugs for CAP Bidding for 2006,” we inadvertently included J7518 (mycophenolic acid), which should be excluded from this list because it is an orally administered immunosuppressive agent rather than a physician-administered drug. We are correcting this error by republishing Addendum B, which reflects the omission of J7518 (mycophenolic acid).
In FR Doc. 05-12938 of July 6, 2005 (70 FR 39022), make the following corrections:
1. On pages 39099 through 39102, Addendum A is corrected to read as follows:
Addendum A—Single Drug Category List
HCPCS Long description Weight J0150 INJECTION, ADENOSINE FOR THERAPEUTIC USE, 6 MG 0.00069338 J0152 INJECTION, ADENOSINE FOR DIAGNOSTIC USE, 30 MG 0.00455133 J0170 INJECTION, ADRENALIN, EPINEPHRINE, 1 ML AMPULE 0.00007823 J0207 INJECTION, AMIFOSTINE, 500 MG 0.00015946 J0215 INJECTION, ALEFACEPT, 0.5 MG 0.00082595 J0280 INJECTION, AMINOPHYLLIN, 250 MG 0.00081312 J0290 INJECTION, AMPICILLIN SODIUM, 500 MG 0.00012537 Start Printed Page 52932 J0475 INJECTION, BACLOFEN, 10 MG 0.00024410 J0540 INJECTION, PENICILLIN G BENZATHINE AND PENICILLIN G PROCAINE, 1,200,000 UNITS 0.00007140 J0550 INJECTION, PENICILLIN G BENZATHINE AND PENICILLIN G PROCAINE, 2,400,000 UNITS 0.00001814 J0570 INJECTION, PENICILLIN G BENZATHINE, 1,200,000 UNITS 0.00004561 J0585 BOTULINUM TOXIN TYPE A, PER UNIT 0.03707810 J0587 BOTULINUM TOXIN TYPE B, PER 100 UNITS 0.00149279 J0600 INJECTION, EDETATE CALCIUM DISODIUM, 1000 MG 0.00004417 J0637 INJECTION, CASPOFUNGIN ACETATE, 5 MG 0.00008403 J0640 INJECTION, LEUCOVORIN CALCIUM, PER 50 MG 0.01054437 J0670 INJECTION, MEPIVACAINE HYDROCHLORIDE, PER 10 ML 0.00038034 J0690 INJECTION, CEFAZOLIN SODIUM, 500 MG 0.00042009 J0692 INJECTION, CEFEPIME HYDROCHLORIDE, 500 MG 0.00024611 J0696 INJECTION, CEFTRIAXONE SODIUM, PER 250 MG 0.00662508 J0698 INJECTION, CEFOTAXIME SODIUM, PER GM 0.00014738 J0702 INJECTION, BETAMETHASONE ACETATE & BETAMETHASONE SODIUM PHOSPHATE, PER 3 MG 0.00284989 J0704 INJECTION, BETAMETHASONE SODIUM PHOSPHATE, PER 4 MG 0.00056519 J0735 INJECTION, CLONIDINE HYDROCHLORIDE, 1 MG 0.00033826 J0800 INJECTION, CORTICOTROPIN, 40 UNITS 0.00360503 J0880 INJECTION, DARBEPOETIN ALFA, 5 MCG 0.11998845 J0895 INJECTION, DEFEROXAMINE MESYLATE, 500 MG 0.00024217 J1000 INJECTION, DEPO-ESTRADIOL CYPIONATE, 5 MG 0.00020815 J1020 INJECTION, METHYLPREDNISOLONE ACETATE, 20 MG 0.00126125 J1030 INJECTION, METHYLPREDNISOLONE ACETATE, 40 MG 0.00587530 J1040 INJECTION, METHYLPREDNISOLONE ACETATE, 80 MG 0.00522812 J1051 INJECTION, MEDROXYPROGESTERONE ACETATE, 50 MG 0.00006464 J1094 INJECTION, DEXAMETHASONE ACETATE, 1 MG 0.00347947 J1100 INJECTION, DEXAMETHASONE SODIUM PHOSPHATE, 1MG 0.05440123 J1190 INJECTION, DEXRAZOXANE HYDROCHLORIDE, PER 250 MG 0.00002421 J1200 INJECTION, DIPHENHYDRAMINE HCL, 50 MG 0.00214443 J1212 INJECTION, DMSO, DIMETHYL SULFOXIDE, 50%, 50 ML 0.00008395 J1245 INJECTION, DIPYRIDAMOLE, PER 10 MG 0.00379554 J1250 INJECTION, DOBUTAMINE HYDROCHLORIDE, PER 250 MG 0.00052679 J1260 INJECTION, DOLASETRON MESYLATE, 10 MG 0.01720675 J1335 INJECTION, ERTAPENEM SODIUM, 500 MG 0.00013138 J1440 INJECTION, FILGRASTIM (G-CSF), 300 MCG 0.00191741 J1441 INJECTION, FILGRASTIM (G-CSF), 480 MCG 0.00403536 J1450 INJECTION FLUCONAZOLE, 200 MG 0.00001593 J1580 INJECTION, GARAMYCIN, GENTAMICIN, 80 MG 0.00039560 J1600 INJECTION, GOLD SODIUM THIOMALATE, 50 MG 0.00005560 J1626 INJECTION, GRANISETRON HYDROCHLORIDE, 100 MCG 0.01469700 J1631 INJECTION, HALOPERIDOL DECANOATE, PER 50 MG 0.00020506 J1642 INJECTION, HEPARIN SODIUM, (HEPARIN LOCK FLUSH), PER 10 UNITS 0.06362003 J1644 INJECTION, HEPARIN SODIUM, PER 1000 UNITS 0.00351209 J1645 INJECTION, DALTEPARIN SODIUM, PER 2500 IU 0.00011417 J1650 INJECTION, ENOXAPARIN SODIUM, 10 MG 0.00134336 J1655 INJECTION, TINZAPARIN SODIUM, 1000 IU 0.00046724 J1710 INJECTION, HYDROCORTISONE SODIUM PHOSPHATE, 50 MG 0.00006029 J1720 INJECTION, HYDROCORTISONE SODIUM SUCCINATE, 100 MG 0.00013201 J1745 INJECTION INFLIXIMAB, 10 MG 0.02736596 J1750 INJECTION, IRON DEXTRAN, 50 MG 0.00244189 J1756 INJECTION, IRON SUCROSE, 1 MG 0.01017283 J1885 INJECTION, KETOROLAC TROMETHAMINE, PER 15 MG 0.00326961 J1940 INJECTION, FUROSEMIDE, 20 MG 0.00064751 J1956 INJECTION, LEVOFLOXACIN, 250 MG 0.00008548 J2001 INJECTION, LIDOCAINE HCL FOR INTRAVENOUS INFUSION, 10 MG 0.00076795 J2010 INJECTION, LINCOMYCIN HCL, 300 MG 0.00061870 J2150 INJECTION, MANNITOL, 25% IN 50 ML 0.00028934 J2260 INJECTION, MILRINONE LACTATE, 5 MG 0.00004912 J2300 INJECTION, NALBUPHINE HYDROCHLORIDE, PER 10 MG 0.00026092 J2324 INJECTION, NESIRITIDE, 0.25 MG 0.00027147 J2353 INJECTION, OCTREOTIDE, DEPOT FORM FOR INTRAMUSCULAR INJECTION, 1 MG 0.00193262 J2354 INJECTION, OCTREOTIDE, NON-DEPOT SUBCUTANEOUS OR INTRAVENOUS INJECTION, 25 MCG 0.00008332 J2405 INJECTION, ONDANSETRON HYDROCHLORIDE, PER 1 MG 0.01360054 J2430 INJECTION, PAMIDRONATE DISODIUM, PER 30 MG 0.00155307 J2505 INJECTION, PEGFILGRASTIM, 6 MG 0.00064498 J2550 INJECTION, PROMETHAZINE HCL, 50 MG 0.00068031 J2680 INJECTION, FLUPHENAZINE DECANOATE, 25 MG 0.00014971 J2765 INJECTION, METOCLOPRAMIDE HCL, 10 MG 0.00011029 J2780 INJECTION, RANITIDINE HYDROCHLORIDE, 25 MG 0.00087713 J2820 INJECTION, SARGRAMOSTIM (GM-CSF), 50 MCG 0.00215849 J2912 INJECTION, SODIUM CHLORIDE, 0.9%, PER 2 ML 0.00673579 J2916 INJECTION, SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE INJECTION, 12.5 MG 0.00060556 Start Printed Page 52933 J2920 INJECTION, METHYLPREDNISOLONE SODIUM SUCCINATE, 40 MG 0.00030935 J2930 INJECTION, METHYLPREDNISOLONE SODIUM SUCCINATE, 125 MG 0.00076469 J2997 INJECTION, ALTEPLASE RECOMBINANT, 1 MG 0.00012123 J3260 INJECTION, TOBRAMYCIN SULFATE, 80 MG 0.00018119 J3301 INJECTION, TRIAMCINOLONE ACETONIDE, PER 10 MG 0.02146050 J3302 INJECTION, TRIAMCINOLONE DIACETATE, PER 5 MG 0.00171576 J3303 INJECTION, TRIAMCINOLONE HEXACETONIDE, PER 5 MG 0.00093708 J3315 INJECTION, TRIPTORELIN PAMOATE, 3.75 MG 0.00000707 J3370 INJECTION, VANCOMYCIN HCL, 500 MG 0.00083391 J3396 INJECTION, VERTEPORFIN, 0.1 MG 0.05387196 J3410 INJECTION, HYDROXYZINE HCL, 25 MG 0.00040617 J3420 INJECTION, VITAMIN B-12 CYANOCOBALAMIN, UP TO 1000 MCG 0.01191674 J3475 INJECTION, MAGNESIUM SULFATE, PER 500 MG 0.00107478 J3480 INJECTION, POTASSIUM CHLORIDE, PER 2 MEQ 0.00213669 J3487 INJECTION, ZOLEDRONIC ACID, 1 MG 0.00333297 J7030 INFUSION, NORMAL SALINE SOLUTION , 1000 CC 0.00101862 J7040 INFUSION, NORMAL SALINE SOLUTION, (500 STERILE ML=1 UNIT) 0.00240866 J7042 5% DEXTROSE/NORMAL SALINE (500 ML = 1 UNIT) 0.00049401 J7050 INFUSION, NORMAL SALINE SOLUTION , 250 CC 0.00983951 J7051 STERILE SALINE OR WATER, 5 CC 0.00695398 J7060 5% DEXTROSE/WATER (500 ML = 1 UNIT) 0.00101887 J7070 INFUSION, D5W, 1000 CC 0.00015744 J7120 RINGERS LACTATE INFUSION, 1000 CC 0.00016820 J7317 SODIUM HYALURONATE, PER 20 TO 25 MG DOSE FOR INTRA-ARTICULAR INJECTION 0.00189786 J7320 HYLAN G-F 20, 16 MG, FOR INTRA ARTICULAR INJECTION 0.00148437 J9000 DOXORUBICIN HCL, 10 MG 0.00233616 J9001 DOXORUBICIN HYDROCHLORIDE, ALL LIPID FORMULATIONS, 10 MG 0.00032228 J9031 BCG (INTRAVESICAL) PER INSTILLATION 0.00048801 J9040 BLEOMYCIN SULFATE, 15 UNITS 0.00003692 J9045 CARBOPLATIN, 50 MG 0.00564705 J9050 CARMUSTINE, 100 MG 0.00000881 J9060 CISPLATIN, POWDER OR S0LUTION, PER 10 MG 0.00094491 J9062 CISPLATIN, 50 MG 0.00025190 J9065 INJECTION, CLADRIBINE, PER 1 MG 0.00008065 J9070 CYCLOPHOSPHAMIDE, 100 MG 0.00062098 J9080 CYCLOPHOSPHAMIDE, 200 MG 0.00004921 J9090 CYCLOPHOSPHAMIDE, 500 MG 0.00008048 J9091 CYCLOPHOSPHAMIDE, 1.0 GRAM 0.00005001 J9092 CYCLOPHOSPHAMIDE, 2.0 GRAM 0.00000525 J9093 CYCLOPHOSPHAMIDE, LYOPHILIZED, 100 MG 0.00091804 J9094 CYCLOPHOSPHAMIDE, LYOPHILIZED, 200 MG 0.00009103 J9095 CYCLOPHOSPHAMIDE, LYOPHILIZED, 500 MG 0.00017529 J9096 CYCLOPHOSPHAMIDE, LYOPHILIZED, 1.0 GRAM 0.00013845 J9097 CYCLOPHOSPHAMIDE, LYOPHILIZED, 2.0 GRAM 0.00001347 J9098 CYTARABINE LIPOSOME, 10 MG 0.00000809 J9100 CYTARABINE, 100 MG 0.00012887 J9110 CYTARABINE, 500 MG 0.00002056 J9130 DACARBAZINE, 100 MG 0.00009340 J9140 DACARBAZINE, 200 MG 0.00006957 J9150 DAUNORUBICIN, 10 MG 0.00000485 J9170 DOCETAXEL, 20 MG 0.00254788 J9178 INJECTION, EPIRUBICIN HCL, 2 MG 0.00120764 J9181 ETOPOSIDE, 10 MG 0.00229277 J9182 ETOPOSIDE, 100 MG 0.00052610 J9185 FLUDARABINE PHOSPHATE, 50 MG 0.00030358 J9190 FLUOROURACIL, 500 MG 0.00392446 J9200 FLOXURIDINE, 500 MG 0.00000405 J9201 GEMCITABINE HCL, 200 MG 0.00491490 J9202 GOSERELIN ACETATE IMPLANT, PER 3.6 MG 0.00285868 J9206 IRINOTECAN, 20 MG 0.00316077 J9208 IFOSFAMIDE, 1 GM 0.00007818 J9209 MESNA, 200 MG 0.00036520 J9211 IDARUBICIN HYDROCHLORIDE, 5 MG 0.00000315 J9213 INTERFERON, ALFA-2A, RECOMBINANT, 3 MILLION UNITS 0.00008006 J9214 INTERFERON, ALFA-2B, RECOMBINANT, 1 MILLION UNITS 0.00668813 J9219 LEUPROLIDE ACETATE IMPLANT, 65 MG 0.00006464 J9245 INJECTION, MELPHALAN HYDROCHLORIDE, 50 MG 0.00000157 J9250 METHOTREXATE SODIUM, 5 MG 0.00184935 J9260 METHOTREXATE SODIUM, 50 MG 0.00050963 J9263 INJECTION, OXALIPLATIN, 0.5 MG 0.07249359 J9265 PACLITAXEL, 30 MG 0.00551428 J9268 PENTOSTATIN, PER 10 MG 0.00000639 Start Printed Page 52934 J9280 MITOMYCIN, 5 MG 0.00004038 J9290 MITOMYCIN, 20 MG 0.00003448 J9291 MITOMYCIN, 40 MG 0.00006085 J9293 INJECTION, MITOXANTRONE HYDROCHLORIDE, PER 5 MG 0.00024882 J9310 RITUXIMAB, 100 MG 0.00405692 J9320 STREPTOZOCIN, 1 GM 0.00000666 J9340 THIOTEPA, 15 MG 0.00002429 J9350 TOPOTECAN, 4 MG 0.00018095 J9355 TRASTUZUMAB, 10 MG 0.00538210 J9360 VINBLASTINE SULFATE, 1 MG 0.00035474 J9370 VINCRISTINE SULFATE, 1 MG 0.00019564 J9375 VINCRISTINE SULFATE, 2 MG 0.00011406 J9390 VINORELBINE TARTRATE, PER 10 MG 0.00109985 J9395 INJECTION, FULVESTRANT, 25 MG 0.00125472 J9600 PORFIMER SODIUM, 75 MG 0.00000029 Q0136 INJECTION, EPOETIN ALPHA, (FOR NON ESRD USE), PER 1000 UNITS 0.24898913 Q0137 INJECTION, DARBEPOETIN ALFA, 1 MCG (NON-ESRD USE) 0.03803750 Q3025 INJECTION, INTERFERON BETA-1A, 11 MCG FOR INTRAMUSCULAR USE 0.00077522 2. On page 39102, Addendum B is corrected to read as follows:
Addendum B—New Drugs for CAP Bidding for 2006
CODE 2005 Description J0128 Abarelix injection. J0180 Agalsidase beta injection. J0878 Daptomycin injection. J1931 Laronidase injection. J2357 Omalizumab injection. J2469 Palonosetron HCl. J2794 Risperidone, long acting. J9035 Bevacizumab injection. J9041 Bortezomib injection. J9055 Cetuximab injection. J9305 Pemetrexed injection. IV. Waiver of Delay in Effective Date
We ordinarily provide an effective date 30 days after the publication of an interim final rule in the Federal Register. We can waive this delay, however, if we find good cause that it is impracticable, unnecessary, or contrary to the public interest and incorporate a statement of the finding and the reasons for it into the notice issued.
We find a delay in the effectiveness of this rule unnecessary because this rule merely provides further clarification of and technical corrections to the interim final rule with comment published July 6, 2005. We also find that a delay in the effectiveness of this interpretation would be contrary to the public interest: a delay in the effectiveness of this rule would defeat the purpose of this rule, which is to delay the implementation of the CAP in order to consider further public comment and issue a final rule before beginning this major new payment system. Therefore, for all of these reasons, we find good cause to waive the delay in the effective date of this rule. It will take effect on the same day as the July 6, 2005 interim final rule with comment.
V. Collection of Information Requirements
This document does not impose information collection and recordkeeping requirements. Consequently, it need not be reviewed by the Office of Management and Budget under the authority of the Paperwork Reduction Act of 1995 (44 U.S.C. 35).
VI. Regulatory Impact Statement
We have examined the impact of this rule as required by Executive Order 12866 (September 1993, Regulatory Planning and Review), the Regulatory Flexibility Act (RFA) (September 19, 1980, Pub. L. 96-354), section 1102(b) of the Social Security Act, the Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4), and Executive Order 13132.
Executive Order 12866 directs agencies to assess all costs and benefits of available regulatory alternatives and, if regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). A regulatory impact analysis (RIA) must be prepared for major rules with economically significant effects ($100 million or more in any 1 year). This rule does not reach the economic threshold and thus is not considered a major rule.
The RFA requires agencies to analyze options for regulatory relief of small businesses. For purposes of the RFA, small entities include small businesses, nonprofit organizations, and small governmental jurisdictions. Most hospitals and most other providers and suppliers are small entities, either by nonprofit status or by having revenues of $6 million to $29 million in any 1 year. Individuals and States are not included in the definition of a small entity. We are not preparing an analysis for the RFA because we have determined that this rule will not have a significant economic impact on a substantial number of small entities.
In addition, section 1102(b) of the Act requires us to prepare a regulatory impact analysis if a rule may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 604 of the RFA. For purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside of a Core-Based Statistical Area and has fewer than 100 beds. We are not preparing an analysis for section 1102(b) of the Act because we have determined that this rule will not have a significant impact on the operations of a substantial number of small rural hospitals.
Section 202 of the Unfunded Mandates Reform Act of 1995 also requires that agencies assess anticipated costs and benefits before issuing any rule that may result in expenditure in any 1 year by State, local, or tribal governments, in the aggregate, or by the private sector, of $110 million. This rule will have no consequential effect on the governments mentioned or on the private sector.
Executive Order 13132 establishes certain requirements that an agency must meet when it promulgates a proposed rule (and subsequent final rule) that imposes substantial direct requirement costs on State and local Start Printed Page 52935governments, preempts State law, or otherwise has Federalism implications. Since this regulation does not impose any costs on State or local governments, the requirements of E.O. 13132 are not applicable.
In accordance with the provisions of Executive Order 12866, this regulation was reviewed by the Office of Management and Budget.
Start Signature(Catalog of Federal Domestic Assistance Program No. 93.773, Medicare—Hospital Insurance; and Program No. 93.774, Medicare—Supplementary Medical Insurance Program)
Dated: August 23, 2005.
Mark B. McClellan,
Administrator, Centers for Medicare & Medicaid Services.
Approved: August 31, 2005.
Michael O. Leavitt,
Secretary.
[FR Doc. 05-17655 Filed 9-1-05; 9:14 am]
BILLING CODE 4120-01-P
Document Information
- Effective Date:
- 9/6/2005
- Published:
- 09/06/2005
- Department:
- Centers for Medicare & Medicaid Services
- Entry Type:
- Rule
- Action:
- Interim final rule; interpretation and correction.
- Document Number:
- 05-17655
- Dates:
- This rule is effective September 6, 2005.
- Pages:
- 52930-52935 (6 pages)
- RINs:
- 0938-AN58: Medicare Part B Competitive Acquisition of Outpatient Drugs and Biologicals (CMS-1325-P)
- RIN Links:
- https://www.federalregister.gov/regulations/0938-AN58/medicare-part-b-competitive-acquisition-of-outpatient-drugs-and-biologicals-cms-1325-p-
- PDF File:
- 05-17655.pdf
- CFR: (1)
- 42 CFR 414